Skip to main content
NVDA-0.13%AAPL+1.07%GOOGL-2.28%MSFT+0.05%AMZN-0.04%TSM-0.83%SPCX-3.86%AVGO-1.13%META+0.80%TSLA-0.43%SKHY+7.05%MU-1.26%BRK-B+0.18%LLY+0.02%JPM+0.34%AMD+3.04%WMT-0.21%V-0.34%XOM+2.24%ASMLa-1.38%JNJ-0.76%INTC+1.69%MA-0.59%0700.HK-1.94%ORCL-0.50%1398.HK+0.79%BAC+0.45%ABBV+0.88%CSCO+0.24%CVX+1.91%COST-0.83%LRCX-1.43%KO-0.92%CAT-0.84%AMAT-0.83%AP2d-0.52%0005.HK-0.78%HSBA.L-1.53%UNH-1.94%DELL+0.29%MS-0.42%PG-2.02%GE-2.83%3988.HK+0.84%1816.HK+0.23%0857.HK-3.26%NFLX-0.96%HD-1.04%GS-0.75%0939.HK+1.66%NZDJPY-2.23%CHFJPY-1.75%USDJPY-1.65%AUDJPY-1.56%EURJPY-1.47%CADJPY-1.46%GBPJPY-1.41%GBPNZD+0.82%EURNZD+0.79%NZDCAD-0.79%AUDNZD+0.70%NZDUSD-0.61%NZDCHF-0.50%GBPTRY+0.41%GBPCHF+0.33%GBPHKD+0.32%GBPMXN-0.28%CADCHF+0.28%EURCHF+0.28%GBPUSD+0.24%EURNOK+0.22%USDNOK+0.21%AUDCHF+0.20%EURZAR+0.20%GBPZAR+0.19%NZDSGD+0.19%USDZAR+0.19%USDCAD-0.17%EURUSD+0.17%USDILS+0.16%CHFNOK+0.15%NZDMXN+0.15%NOKJPY-0.13%GBPAUD+0.12%AUDCAD-0.12%USDTHB+0.12%USDCHF+0.11%USDTRY+0.11%AUDDKK-0.11%AUDNOK+0.11%AUDUSD+0.09%EURCZK-0.09%EURAUD+0.08%EURSGD+0.07%USDSGD+0.07%USDPLN+0.07%GBPSGD+0.07%EURPLN+0.07%EURSEK+0.05%USDMXN+0.05%USDSEK+0.04%EURGBP-0.04%USDCOP-0.04%AUDSGD-0.04%USDCNH-0.03%GBPCAD+0.03%PLNJPY+0.02%CHFSEK-0.02%EURCAD-0.01%SGDJPY+0.01%USDHKD+0.01%CHFSGD+0.01%EURCNH-0.01%EURHKD-0.01%EURDKK0.00%USDDKK0.00%COFFEE-2.20%SUGAR+1.96%XPTUSD-1.60%COTTON+1.41%GAGUSD-0.93%XAGUSD-0.93%COCOA-0.74%USOIL+0.68%S1+0.59%C1+0.52%UKOIL+0.47%HG1-0.38%BTCUSD-0.40%ETHUSD+0.11%USDTUSD-0.03%XRPUSD-1.20%SOLUSD-0.37%TRXUSDT+0.39%ZECUSDT-1.66%DOGEUSD-1.39%XMRUSDT-0.81%LINKUSD-0.02%XLMUSD-0.97%BCHUSDT-1.73%LTCUSD-1.51%UNIUSD-1.99%TONUSD+24.88%HBARUSDT-1.20%SUIUSD-1.19%TAOUSDT-0.84%AAVEUSD-1.48%DOTUSDT-2.09%ICPUSDT-1.01%ONDOUSDT-1.87%WLDUSDT-1.71%ATOMUSDT-2.11%ARBUSDT-0.18%JUPUSDT-2.53%INJUSDT-2.55%STXUSDT-2.70%FETUSDT-2.09%TIAUSDT-0.60%SEIUSDT-1.80%PYTHUSDT-1.11%IMXUSDT-2.27%WIFUSDT-2.93%GRTUSDT-2.01%OPUSDT-1.99%POLUSDT-3.13%IOTAUSDT-2.34%AXSUSDT-1.82%FARTCOINUSDT-1.40%EOSUSDT+0.12%DYDXUSDT-0.37%ORDIUSDT+0.74%GALAUSDT-2.53%NOTUSDT-0.68%RONINUSDT-0.71%NVDA-0.13%AAPL+1.07%GOOGL-2.28%MSFT+0.05%AMZN-0.04%TSM-0.83%SPCX-3.86%AVGO-1.13%META+0.80%TSLA-0.43%SKHY+7.05%MU-1.26%BRK-B+0.18%LLY+0.02%JPM+0.34%AMD+3.04%WMT-0.21%V-0.34%XOM+2.24%ASMLa-1.38%JNJ-0.76%INTC+1.69%MA-0.59%0700.HK-1.94%ORCL-0.50%1398.HK+0.79%BAC+0.45%ABBV+0.88%CSCO+0.24%CVX+1.91%COST-0.83%LRCX-1.43%KO-0.92%CAT-0.84%AMAT-0.83%AP2d-0.52%0005.HK-0.78%HSBA.L-1.53%UNH-1.94%DELL+0.29%MS-0.42%PG-2.02%GE-2.83%3988.HK+0.84%1816.HK+0.23%0857.HK-3.26%NFLX-0.96%HD-1.04%GS-0.75%0939.HK+1.66%NZDJPY-2.23%CHFJPY-1.75%USDJPY-1.65%AUDJPY-1.56%EURJPY-1.47%CADJPY-1.46%GBPJPY-1.41%GBPNZD+0.82%EURNZD+0.79%NZDCAD-0.79%AUDNZD+0.70%NZDUSD-0.61%NZDCHF-0.50%GBPTRY+0.41%GBPCHF+0.33%GBPHKD+0.32%GBPMXN-0.28%CADCHF+0.28%EURCHF+0.28%GBPUSD+0.24%EURNOK+0.22%USDNOK+0.21%AUDCHF+0.20%EURZAR+0.20%GBPZAR+0.19%NZDSGD+0.19%USDZAR+0.19%USDCAD-0.17%EURUSD+0.17%USDILS+0.16%CHFNOK+0.15%NZDMXN+0.15%NOKJPY-0.13%GBPAUD+0.12%AUDCAD-0.12%USDTHB+0.12%USDCHF+0.11%USDTRY+0.11%AUDDKK-0.11%AUDNOK+0.11%AUDUSD+0.09%EURCZK-0.09%EURAUD+0.08%EURSGD+0.07%USDSGD+0.07%USDPLN+0.07%GBPSGD+0.07%EURPLN+0.07%EURSEK+0.05%USDMXN+0.05%USDSEK+0.04%EURGBP-0.04%USDCOP-0.04%AUDSGD-0.04%USDCNH-0.03%GBPCAD+0.03%PLNJPY+0.02%CHFSEK-0.02%EURCAD-0.01%SGDJPY+0.01%USDHKD+0.01%CHFSGD+0.01%EURCNH-0.01%EURHKD-0.01%EURDKK0.00%USDDKK0.00%COFFEE-2.20%SUGAR+1.96%XPTUSD-1.60%COTTON+1.41%GAGUSD-0.93%XAGUSD-0.93%COCOA-0.74%USOIL+0.68%S1+0.59%C1+0.52%UKOIL+0.47%HG1-0.38%BTCUSD-0.40%ETHUSD+0.11%USDTUSD-0.03%XRPUSD-1.20%SOLUSD-0.37%TRXUSDT+0.39%ZECUSDT-1.66%DOGEUSD-1.39%XMRUSDT-0.81%LINKUSD-0.02%XLMUSD-0.97%BCHUSDT-1.73%LTCUSD-1.51%UNIUSD-1.99%TONUSD+24.88%HBARUSDT-1.20%SUIUSD-1.19%TAOUSDT-0.84%AAVEUSD-1.48%DOTUSDT-2.09%ICPUSDT-1.01%ONDOUSDT-1.87%WLDUSDT-1.71%ATOMUSDT-2.11%ARBUSDT-0.18%JUPUSDT-2.53%INJUSDT-2.55%STXUSDT-2.70%FETUSDT-2.09%TIAUSDT-0.60%SEIUSDT-1.80%PYTHUSDT-1.11%IMXUSDT-2.27%WIFUSDT-2.93%GRTUSDT-2.01%OPUSDT-1.99%POLUSDT-3.13%IOTAUSDT-2.34%AXSUSDT-1.82%FARTCOINUSDT-1.40%EOSUSDT+0.12%DYDXUSDT-0.37%ORDIUSDT+0.74%GALAUSDT-2.53%NOTUSDT-0.68%RONINUSDT-0.71%
SA

Savara Inc. (SVRA)

NASDAQ • Healthcare

$5.42
-$0.11 (-2.0%)
Market closed

Last close at September 9, 2026 at 20:00 UTC

Open$5.48
Day Range$5.37 - $5.57
Avg. Volume (3M)1.5M
Market Cap$1.1B
52 Week Range
$3.34$7.01
Next EarningsIn 62 daysNov 11, 2026

Metrics Over Time

Fundamentals & Financials

Revenue (TTM)
$0
Net Income (TTM)
-$139.3M
EPS (TTM)
-$0.58
ROA (TTM)
-72.5%
Current Ratio
10.13
Dividend Yield
0%

TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.

Earnings

-8.3%Q1 2026-$0.13
-7.1%Q2 2026-$0.15
-13.3%Q3 2026-$0.16
Next

Nov 11

in 62 daysQ4 2026

% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS

Latest report — Q3 2026
Miss -13.3%

Savara’s loss per share trailed consensus in the second fiscal quarter of 2026, based on preliminary results reported August 11, 2026, with EPS of -$0.16 trailing the -$0.14 estimate (difference -$0.02) and down from -$0.14 a year ago. The biotech, which is centered on its molgramostim program for uncommon respiratory conditions, posted GAAP net income of roughly -$40.2 million, a wider loss (net_income YoY -32.3%) versus about -$30.4 million a year earlier, alongside GAAP operating income of around -$41.0 million. Cash burn remained visible, with negative operating cash flow of about -$29.7 million during the quarter, and the company repurchased about $0.0 million of stock. Looking ahead, next-period consensus calls for EPS of -$0.16 on revenue of $500,000.00.

View full earnings history

About Savara Inc.

Savara Inc. is a NASDAQ-listed Biotechnology company focused on medicines for uncommon respiratory conditions. The company centers its work on molgramostim, an inhaled form of granulocyte-macrophage colony-stimulating factor, and it operates as a small-cap developer rather than a commercial diversified drugmaker.

Name
Savara Inc.
CEO
Matthew Pauls
Website
www.savarapharma.com
Industry
Healthcare
Employees
70

Today's Snapshot

AI-generated

SVRA closed 2.1% lower at 5.42, while its sector was flat.

Trading Volume

Below 10d avg (1.3M)

1M

vs S&P 500 Today

Underperforming Market

-1.66%

Updated: September 9, 2026 at 20:07 UTC

Technical Indicators

1 Buy3 Neutral4 Sell
SVRA presents a mildly bearish picture driven more by price placement than by a strong trend, with short-term averages sitting above the market and the 200-day average still slightly supportive. Momentum readings are muted and near neutral, the MACD is flat and RSI is around midrange, while volume as measured by OBV shows accumulation that conflicts with the sell bias. ADX indicates a weak trend and ATR points to moderate intraday range, with the pivot area near 5.47 offering short-term resistance. Technical takeaway: Sell — short-term pressure amid muted trend strength and mixed volume signals.
All signals
  • EMA (5 indicators)$5.32 - $5.51
    Sell
  • RSI (14)47.46
    Neutral
  • Stochastic %K (14, 3, 3)44.77
    Neutral
  • MACD Level (12, 26)-0.04
    Neutral

Peers & Related Assets

TNGXTango Therapeutics, Inc.
$24+5.7%
BCAXBicara Therapeutics Inc. Common Stock
$23.64-0.3%
TYRATyra Biosciences, Inc.
$22.01-17.7%
KURAKura Oncology, Inc.
$12.09-3.4%
GERNGeron Corporation
$1.4-7.3%
EYPTEyePoint Pharmaceuticals, Inc.
$4.34-4.8%
Stay Ahead of the Market

Get premium market insights delivered directly to your inbox.